Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals Limited announced the release of 684,437 ordinary shares from voluntary escrow, which were initially issued to ImaginAb Inc. as part of an asset acquisition. This release, scheduled for May 29, 2025, is in accordance with ASX Listing Rule 3.10A and may impact the company’s operations by increasing share liquidity. The move reflects Telix’s ongoing strategic efforts to enhance its market positioning and could have implications for stakeholders by potentially influencing share value and investor confidence.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company focuses on addressing significant unmet medical needs in oncology and rare diseases, with a portfolio of clinical and commercial stage products.
YTD Price Performance: 5.65%
Average Trading Volume: 1,991,015
Technical Sentiment Signal: Buy
Current Market Cap: A$8.79B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.